Wakefulness-Promoting Agents – Sunosi Prior Authorization with Step Therapy Policy - (CNF640)
Defines Cigna's prior authorization and step therapy requirements for Sunosi (solriamfetol) for treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea in adults, including required prior therapies, diagnostic confirmation, prescriber type, treatment duration of approval, and disallowed concomitant use.
Narcolepsy criteria updated to include central nervous system (CNS) stimulants as an option for required prior therapy before Sunosi; previously only generic modafinil or armodafinil were required.
OSA criteria changed to require use in conjunction with positive airway pressure or inability to initiate/tolerate positive airway pressure (expanded language from continuous PAP).
Exceptions were added so patients currently receiving Sunosi do not need to have tried step therapy comparators.
Review date updated to 04/15/2026 with Early Annual Revision noting changes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.